General Information of Drug (ID: DMQXL1T)

Drug Name
CT 327 Drug Info
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Phase 2 [1]
Psoriasis vulgaris EA90 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMQXL1T

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Entrectinib DMMPTLH Non-small-cell lung cancer 2C25 Approved [4]
Repotrectinib DM9FB2T Non-small-cell lung cancer 2C25 Approved [5]
Larotrectinib DM26CQR Solid tumour/cancer 2A00-2F9Z Approved [6]
MIM-D3 DMZHN5B Alzheimer disease 8A20 Phase 3 [7]
SNA-120 DMPN314 Plaque psoriasis EA90.0 Phase 2 [8]
ONO-7579 DMXLPYE Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
Altiratinib DMUJCBT Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
PLX7486 DM0IVGU Pancreatic cancer 2C10 Phase 1 [10]
DS-6051 DM0RD4F Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
LOXO-195 DMDXFBJ Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tropomyosin-related kinase A (TrkA) TTTDVOJ NTRK1_HUMAN Inhibitor [3]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01808157) A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis. U.S. National Institutes of Health.
3 Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
7 Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
10 National Cancer Institute Drug Dictionary (drug id 747694).
11 National Cancer Institute Drug Dictionary (drug id 766123).